...
首页> 外文期刊>Biochimica et biophysica acta. Molecular basis of disease: BBA >Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells
【24h】

Statin blocks Rho/Rho-kinase signalling and disrupts the actin cytoskeleton: relationship to enhancement of LPS-mediated nitric oxide synthesis in vascular smooth muscle cells

机译:他汀类药物阻断Rho / Rho激酶信号传导并破坏肌动蛋白细胞骨架:与增强血管平滑肌细胞中LPS介导的一氧化氮合成的关系

获取原文
获取原文并翻译 | 示例
           

摘要

We previously demonstrated statins to enhance cytokine-mediated nitric oxide (NO) synthesis in vascular smooth muscle cells (VSMC). To clarify the mechanism by which this occurs, we evaluated the effects of fluvastatin in lipopolysaccharide (LPS)-stimulated VSMC. NO production induced by LPS was dose-dependently enhanced by fluvastatin, as were iNOS mRNA levels and iNOS protein expression. Exogenous mevalonate and geranylgeranylpyrophosphate (GGPP) dampened the stimulatory effect of fluvastatin. A pull-down assay demonstrated fluvastatin to decrease levels of GTP-bound Rho A. Moreover, a Rho-kinase inhibitor, Y-27632, was observed to enhance LPS-induced NO production. We recently demonstrated that disrupting F-actin formation dramatically potentiates the ability of LPS to induce iNOS mRNA and protein expression. In the present study, staining of F-actin with nitrobenzoxadiazole (NBD)-phallacidin demonstrated that fluvastatin significantly impairs F-actin stress fiber formation. In light of these results, the ability of statins to increase NO production is due, at least in part, to their ability to block the biosynthesis of mevalonate, thereby preventing isoprenoid biosynthesis. This inhibits Rho/Rho-kinase signalling and, in turn, disrupts the actin cytoskeleton. Further analysis of the signalling pathway by which the actin cytoskeleton affects iNOS expression might yield new insight into mechanisms of regulation of NO production. (C) 2004 Elsevier B.V. All rights reserved.
机译:我们先前证明了他汀类药物可增强血管平滑肌细胞(VSMC)中细胞因子介导的一氧化氮(NO)合成。为了阐明这种情况发生的机理,我们评估了氟伐他汀在脂多糖(LPS)刺激的VSMC中的作用。氟伐他汀可剂量依赖性地增强LPS诱导的NO产生,iNOS mRNA水平和iNOS蛋白表达也是如此。外源性甲羟戊酸酯和香叶基香叶基焦磷酸酯(GGPP)抑制了氟伐他汀的刺激作用。下拉测定法显示氟伐他汀可降低GTP结合的Rho A的水平。此外,观察到Rho激酶抑制剂Y-27632可增强LPS诱导的NO产生。我们最近证明破坏F-肌动蛋白的形成大大增强了LPS诱导iNOS mRNA和蛋白质表达的能力。在本研究中,用硝基苯并恶二唑(NBD)-phallacidin对F-肌动蛋白染色表明,氟伐他汀显着损害F-肌动蛋白应激纤维的形成。根据这些结果,他汀类药物增加NO产生的能力至少部分是由于它们阻断甲羟戊酸的生物合成的能力,从而阻止了类异戊二烯的生物合成。这会抑制Rho / Rho激酶信号传导,进而破坏肌动蛋白的细胞骨架。肌动蛋白细胞骨架影响iNOS表达的信号传导途径的进一步分析可能会产生对NO产生调节机制的新见解。 (C)2004 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号